A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. - Wikidata - wikimedia - TriplyDB

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

http://www.wikidata.org/entity/Q35020652

about

The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas Targeting the mTOR signaling pathway in neuroendocrine tumors A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors Pancreatic neuroendocrine tumors: a review.Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.

P2860

Q26740374-C2AB4100-E082-457F-9B3F-2FF9CB993683 Q26752757-16A36B3E-8DC5-4AE8-BB95-780733B9D261 Q26852089-60C6DA79-88AB-44A3-9DCF-DEE9873221CD Q30301096-92F57274-3340-4BC6-BA08-5EDA3BFAD191 Q30364864-01EBC0B6-D35C-4EA3-9D72-CC8ECE69C539 Q30884794-81C41550-8014-4929-A58B-1DD3175187FD Q35677887-AAB84137-2746-4D63-A7E6-2C0901E5A2FD Q36107481-1141CAD3-2D33-4F9D-9242-3CDC4F7CD8A9 Q38372459-007A8708-9801-4F07-A1DE-6E441CBF33B1 Q38400485-27643870-3CC8-48BB-9C82-A6591428D38F Q38527936-32EF67D1-E140-4AD1-BF1E-541211390125 Q38835123-36E18EF6-E2F9-44E7-9A3E-B73C0C0AE8C0 Q38842250-7E9335AE-4C75-4BE0-B96D-1475A66D7C2F Q41559421-9E6F8C08-AD82-48BC-9D21-15388E051A08 Q42379480-0B957201-D327-4B39-B563-BFE801E6594B Q44425475-02A54FCC-70DA-40B1-B9BC-87597C1DC6B2 Q48295398-2B9A8F57-F18C-4DEE-867E-FCF59D5B75A3 Q51122180-AB1BB136-B800-4AC0-970F-2A611920AB94

P2860

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

http://www.wikidata.org/entity/Q35020652

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.

@ast

A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.

@en

type

label

A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.

@ast

A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.

@en

prefLabel

A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.

@ast

A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.

@en

P1433

Q35020652-EDBB74C6-CC00-459C-8542-47F679557E32

P1476

Q35020652-F6BAD220-BB80-405D-A633-EA5D8E48EACF

P2093

Q35020652-1A1C98F1-9A72-4EAA-8E1E-CF2B20FD26F7

Q35020652-1C01D087-349A-413F-B6FA-BB0B76E8D0AC

Q35020652-8E3AD77D-11C5-4A24-BE5C-77496AA9221A

Q35020652-9786EC06-7AC5-41F6-AF18-03A535AD235B

Q35020652-9D3ED64E-DF59-49BB-AC43-B23B61EEA73C

Q35020652-ABE40F06-20CB-4790-B252-26B5631C2C09

Q35020652-AFD3C330-155C-49E6-ABF0-AEF9B57A0498

Q35020652-B5D5E515-B646-4132-8ED6-3070257D9A5D

Q35020652-CA52619A-6A5C-410F-93C8-79DA3D0D1B4B

Q35020652-E09BDE6F-2EE8-42A8-B14A-420A09F0E099

P2860

Q35020652-22884161-3457-4716-BC65-231BE8C05771

Q35020652-26C6ED35-5502-4960-B5AB-AE041088D95B

Q35020652-289705C4-1C3D-41ED-9BD3-19ACEB96C059

Q35020652-31C8812F-1443-47B8-864F-F7D449DA152B

Q35020652-4927AAF2-F96D-4D7D-B590-1B024929A0F5

Q35020652-6E92B759-CC96-40AF-903E-DB235388E923

Q35020652-6E95D5CC-F598-4D4A-841E-F0D6A9A82882

Q35020652-8A5EAD21-193F-4492-ABC1-B62357D9D8A3

Q35020652-98159BD2-AC49-431F-B605-57867E28147D

Q35020652-A5899A50-1FAA-4854-BF9B-362A959EF8FE

P304

Q35020652-02C84AFD-7470-4209-B644-36ACE611ACB4

P31

Q35020652-4DBB3727-1759-456C-ABCB-044FCA8F8CAE

P356

Q35020652-A934A25A-720A-4B35-9185-94BD11B4F683

P407

Q35020652-0AE5D7BE-3925-4136-B14E-49A9B5B0DB5B

P433

Q35020652-B37FFFBA-3743-4FAD-95FA-8A65AD70342E

P478

Q35020652-AC76E63F-30BB-4824-95C9-E73F61E217C3

P50

Q35020652-FA0D0E42-710A-4AD3-9ED9-420A1C3117E4

P577

Q35020652-4627DE7B-BBF0-4B94-9F68-6FB44953E852

P698

Q35020652-F026D83F-B114-423B-94F4-F266A26B1E77

P932

Q35020652-7D0B36D2-4832-4A34-A235-BA1B2D12D0D2

P356

P1433

P1476

A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

David P Ryan

http://www.w3.org/2001/XMLSchema#string

Eileen Regan

http://www.w3.org/2001/XMLSchema#string

Hui Zheng

http://www.w3.org/2001/XMLSchema#string

Jennifer A Chan

http://www.w3.org/2001/XMLSchema#string

Jill Allen

http://www.w3.org/2001/XMLSchema#string

Keith Stuart

http://www.w3.org/2001/XMLSchema#string

Lawrence Blaszkowsky

http://www.w3.org/2001/XMLSchema#string

Marielle Gonzalez

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

P2860

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Immunoregulatory functions of mTOR inhibition.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

P304

3212-3218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28142

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey A Meyerhardt

P577

2013-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23733618

http://www.w3.org/2001/XMLSchema#string

P932

4308727

http://www.w3.org/2001/XMLSchema#string